剂量提升放疗与预防性扩大野淋巴结照射对FIGO IIIB期宫颈癌患者预后有益
该回顾性分析纳入223例FIGO IIIB期宫颈癌患者,评估同步放化疗的疗效、治疗失败、毒性与预后因素。结果显示完全缓解207例(92.8%)、部分缓解16例(7.2%),5年OS、DFS、LCR、DMFS分别为61.1%、55.2%、83.6%、66.4%。作者认为A点EQD2剂量提升可显著改善OS、DFS和LCR,无腹主动脉旁淋巴结转移者接受预防性扩大野照射的DFS有显著生存优势。
要点
- A点EQD2剂量提升可显著改善FIGO IIIB期宫颈癌患者的OS、DFS和LCR。
- 无腹主动脉旁淋巴结转移者接受预防性扩大野照射的DFS有显著生存优势,OS和DMFS有改善趋势。
- 作者建议FIGO IIIB期宫颈癌患者接受更高EQD2(≥98Gy10)放疗。
核心结论
- 作者认为FIGO IIIB期宫颈癌患者应接受更高EQD2(≥98Gy10)放疗。
- 作者认为无腹主动脉旁淋巴结转移的患者应接受预防性扩大野淋巴结照射以改善预后。
研究设计与样本
- 回顾性分析纳入223例病理亚型、年龄、治疗前血红蛋白水平、肿瘤大小、盆腔淋巴结转移、腹主动脉旁淋巴结转移、外照射技术、治疗时长、A点EQD2剂量及同步化疗周期明确的FIGO IIIB期宫颈癌患者。
- 采用单因素和多因素分析分别研究上述因素与OS、DFS、LCR、DMFS的相关性。
主要发现
- 全组达到完全缓解207例(92.8%)、部分缓解16例(7.2%),不良反应可接受。
- 全组5年OS、DFS、LCR、DMFS分别为61.1%、55.2%、83.6%、66.4%。
- A点EQD2剂量提升可显著改善OS、DFS和LCR。
- 无腹主动脉旁淋巴结转移且接受预防性扩大野照射的患者DFS有显著生存优势,OS和DMFS有改善趋势。
关键数值与推荐
- 作者建议FIGO IIIB期宫颈癌患者接受更高EQD2(≥98Gy10)放疗。
- 作者建议无腹主动脉旁淋巴结转移的患者接受预防性扩大野淋巴结照射以改善预后。
临床怎么用
- 作者认为FIGO IIIB期宫颈癌患者应接受更高EQD2(≥98Gy10)放疗。
- 作者认为无腹主动脉旁淋巴结转移的患者应接受预防性扩大野淋巴结照射以改善预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, the standard treatment for locally advanced cervical cancer patients is concurrent chemoradiotherapy. Here we aim to evaluate therapeutic efficacy, treatment failure, toxicity and prognostic factors for FIGO IIIB cervical cancer patients. METHODS: A comprehensive retrospective analysis was performed to understand various factors which contribute to IIIB cervical cancer prognosis. In total 223 well defined patients were assigned according to their pathological subtype, age, pre-treatment HGB level, tumor size, pelvic lymph node (LN) metastasis, para-aortic LN metastasis as well as external irradiation technologies, treatment duration, point A EQD2 dose and concurrent chemotherapy cycles. We then performed correlation studies of these factors and OS, DFS, LCR, DMFS using univariate and multivariate analysis respectively. RESULTS: We managed to achieve 207 (92.8%) complete response (CR) and 16 (7.2%) partial response (PR) with acceptable adverse effects. Notably, the 5 years OS, DFS, LCR, DMFS for these patients were 61.1, 55.2, 83.6 and 66.4% respectively. Importantly, our studies suggest that escalated point A EQD2 can significantly improve OS, DFS and LCR for FIGO IIIB cervical cancer patients, furthermore, patients without para-aortic LN metastasis who received prophylactic extended field irradiation have significant survival advantage for DFS and a tendency to improve OS and DMFS. CONCLUSIONS: Our results suggest that FIGO IIIB cervical cancer patients should receive higher EQD2 (≥98Gy10) radiotherapy, moreover, patients without para-aortic LN metastasis should receive prophylactic extended field nodal irradiation to improve prognosis.
引用
- Meng Q, Wang W, Liu X, et al. Escalated radiation and prophylactic extended field nodal irradiation are beneficial for FIGO IIIB cervical cancer patients' prognosis. Radiat Oncol. 2018. PMID: 30453993. doi:10.1186/s13014-018-1172-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。